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Background: The cytokine growth differentiation factor-15 (GDF-15), a member of the TGF beta superfamily, has
recently been discovered to play an important role in cardiovascular diseases. It is mostly expressed in
macrophages of atherosclerotic lesions, but its impact on advanced atherosclerosis is still unknown. This study was
performed to evaluate the effects of GDF-15 in an established mouse model of advanced atherosclerosis.
Methods: Thirty-eight LDL receptor deficient mice received a lethal body radiation. Half of the group was
transplanted with bone marrow of GDF-15 deficient mice. Nineteen mice were transplanted with bone marrow
from wild-type controls. After 24 weeks on an atherogenic diet, animals were euthanized and sections of the aortic
sinus were prepared. Lesion size and lesion composition, as well as macrophage content,were evaluated.
Results: While demonstrating no difference in lesion size, LDL-receptor knockout mice transplanted with bone
marrow from GDF-15 deficient mice showed enhanced macrophage accumulation and features of atherosclerotic
plaque destabilization, such as thinning of fibrous caps. Immunostaining against intercellular adhesion molecule-1
further revealed an increased expression in mice receiving GDF-15-deficient bone marrow.
Conclusions: This is the first study that demonstrates a protective role of GDF-15 in advanced atherosclerosis and
macrophage accumulation, possibly due to the reduced expression of adhesion molecules.Background
Cytokines are known to play a key role in the develop-
ment and progression of atherosclerosis [1]. Among
these, members of the transforming growth factor-β
(TGF-β) superfamily have been shown to contribute to
the development of vascular inflammation [2,3]. Re-
cently, growth differentiation factor-15 (GDF-15), a
member of the TGF-β family, has been identified to par-
ticipate in cardiovascular pathology. GDF-15, also known
as macrophage inhibitory cytokine-1, prostate-derived fac-
tor or non-steroidal anti-inflammatory drug-activated
gene-1, is a 12-kDa secreted protein (and a 25-kDa
disulfide-linked dimer) which is, besides in placenta and
prostate, not expressed under basal conditions. It can be
induced by inflammation, injury, and malignancy [4,5].* Correspondence: florian.bea@klf-net.de
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reproduction in any medium, provided the orFurthermore, GDF-15 is involved in apoptosis and cardiac
hypertrophy, and can be induced by biomechanical stretch
[6-9]. In addition, several clinical studies have investigated
its role in cardiovascular diseases. GDF-15 is described as
a novel biomarker with a high impact on risk stratification
and prognostic value in myocardial infarction, chronic
heart failure, and pulmonary embolism [10-13]. The
mechanisms through which GDF-15 acts, however, seem
complex and are still unclear. In atherosclerotic lesion de-
velopment, most experimental studies have demonstrated
the anti-atherogenic properties of TGF-β [14,15]; however,
these have not been defined for the different members of
the TGF-β superfamily [2,16]. Recently, a study by de Jager
et al.demonstrated an anti-atherosclerotic effect of GDF-
15 deficiency in low-density lipoprotein (LDL)r−/− mice 4
and 12 weeks after initiation of a hyperlipidemic diet [17].
However, it is not known how GDF-15 acts in the ad-
vanced stages of atherosclerosis that we often find in hu-
man disease. In the present study, we tested whether
GDF-15 alters lesion size and lesion composition in an ad-
vanced stage of atherosclerosis.l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Animals and bone marrow transplantation
Eight-week-old female LDL-receptor−/− mice (LDLr−/−,
background C57/BL/6; Jackson Laboratory, Bar Harbor,
USA; n=38) received lethal body irradiation at a dose of
9 Gy. Half of the group (n=19) was transplanted with
bone marrow of mice (n=5) with a GDF-15 knock-out
[18]. Nineteen LDLr−/− mice were used as controls,
which were transplanted with bone marrow of wild-type
mice (C57/BL/6CR). After transplantation, mice were
fed a high fat western-type diet (Altromin, Lage/
Germany; Nr. 11320010: 0.15% cholesterol) for 24
weeks. Animals were kept within the animal care facility
of the University of Heidelberg. The investigation con-
forms to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of
Health (NIH Publication No. 85–23, revised 1996). The
housing and care and procedures in the study were
performed in accordance with the guidelines and regu-
lations composed by the Animal Care Committee of
the University of Heidelberg and approved by the
Regierungspraesidium Karlsruhe.
Animal sacrifice and preparation of tissues
After 24 weeks on a high cholesterol Western-type diet,
mice were heavily sedated (Avertin, Aldrich, Milwaukee,
USA), blood was collected from the inferior vena cava,
and the animals were sacrificed by exsanguination
(fasted 3 h prior to sacrifice). The animals were perfused
with 10 mL phosphate-buffered saline, followed by a
perfusion with 4% buffered formalin via the left ven-
tricle. The entire heart from each animal was dissected
out, embedded in paraffin, and the aortic sinus was seri-
ally sectioned (5 μm). Every fifth section was stained
with a modified Movat’s pentachrome stain [19].
Assessment of chimerism
The reconstitution of the transplanted bone marrow was
determined by PCR on liver and spleen tissue.
Determination of plasma lipid concentration
Total serum cholesterol, high-density lipoprotein (HDL),
LDL cholesterol, and triglycerides were determined en-
zymatically in heparinized plasma.Table 1 Distribution of body weight, total serum cholesterol,
of recipients of GDF-15−/−bone marrow (GDF-15−/−) and wild-




GDF-15 +/+ (WT)(n=15) 28±1 351±28
GDF-15 −/− (KO)(n=17) 29±1 364±15
Quantitative evaluation of lesion size within the aortic root also showed no significa
WT: wild-type (recipients of bone marrow from C57/Black 6 control mice); KO: knocEvaluation of lesion size and lesion composition
Two investigators who were blinded to the study proto-
col determined the cross-sectional area of the lesion in
each section by using computer-assisted morphometry
(Image Pro, Media Cybernetics, Silver Spring, USA); this
is reported as mean plaque area per animal (data
expressed in μm2). We further evaluated each section
for characteristic features of plaque morphology/com-
position: thickness of the fibrous cap (presented as μm),
size of the necrotic core (a large necrotic core was de-
fined as occupying more than 50% of the plaque’s vol-
ume and was measured by computer). Calcification was
determined using von Kossa staining [20].
Immunohistochemistry
Detection of monocytes/macrophages was performed
using monoclonal goat anti-mouse antibody (anti-Mac-2,
Accurate, NY, USA) and detection of ICAM-1 by using a
polyclonal antibody (Santa Cruz Biotech, CA, USA). Sec-
tions were incubated with the biotinylated secondary anti-
body, rinsed three times with PBS, and incubated for 10
minutes with streptavidin at room temperature. AEC-
chromogen substrate (Invitrogen, Karlsruhe, Germany)
was used for visualization. The extent of positive staining
within the lesions was determined using computer-
assisted morphometry and is presented as ratio stained
area/total lesion area (Image Pro, Media Cybernetics,
Silver Spring, USA).
Statistical analysis
All data were expressed as mean ± SEM. Differences be-
tween means in plasma lipid profiles were determined
with the two-tailed unpaired student’s t-test. For analysis
of plaque morphometry and areas of positive staining,
groups were compared using the two-tailed Mann–
Whitney U test. For evaluation of plaque morphology,
groups were compared using the χ2test. A p value <0.05
was considered statistically significant.
Results
Effect of bone marrow transplantation
Polymerase chain reaction analysis of the bone marrow
demonstrated a complete conversion of the original
LDLr−/− genotype to the donors’ type, indicating that the
bone marrow population had been reconstituted (dataLDL cholesterol, HDL cholesterol, and serum triglycerides








293±26 25±2 159±20 246,566±14,788†
309±14 28±3 134±5 203,079±17,898†
nt difference between the groups (p=0.08); Mean±SEM; †p=0.08.













































































Figure 1 Enhanced macrophage accumulation and ICAM-1
expression within the atherosclerotic lesions of mice
transplanted with bone marrow from GDF-15−/− donors.
(A) Video-microscopic evaluation of positive staining for macrophages
(Mac-2-staining) showed significant enhanced macrophage
accumulation within the atherosclerotic lesions of LDLr−/− mice
transplanted with bone marrow from GDF-15−/− mice in comparison
to wild-type controls (p<0.01). Data are presented as ratio positive
macrophage staining/lesion; Mean±SEM. (B) Video-microscopic
evaluation of positive staining for ICAM-1 demonstrated a significant
enhanced expression within atherosclerotic lesions of LDLr−/− mice
transplanted with bone marrow from GDF-15−/− mice compared to
wild-type controls (p<0.01). Data are presented as ratio positive ICAM-1
staining/lesion; Mean±SEM. (C) Atherosclerotic lesions of LDL−/− mice
transplanted with bone marrow from GDF-15−/− donors (p<0.01)
showed a significantly thinner fibrous cap than controls. Data are
presented as μm thickness; Mean±SEM.
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and mortality between the groups.
Effect on plasma lipid level and body weight
There were no significant differences in total cholesterol,
LDL, HDL, and triglycerides between mice that received
GDF-15−/− bone marrow and controls. Furthermore,
there was no difference in body weight (Table 1).
Mean lesion area
After 24 weeks on the western type diet, the extent of
atherosclerotic lesion development in the aortic sinus
was evaluated. We could not detect any significant dif-
ference in lesion size (GDF-15+/+246.566±14.788 μm2
versus GDF-15−/−203.079±17.898 μm2, p= 0.08; Table 1).
Enhanced macrophage content in GDF-15 deficient mice
After 24 weeks on the western-type diet, we were able to
demonstrate macrophage rich lesions and enhanced
foam cell formation evaluated by macrophage staining in
both groups. Mice transplanted with bone marrow of
GDF-15−/− donors showed enhanced macrophage accu-
mulation within atherosclerotic lesions (0.51 versus 0.31;
p<0.01; Figures 1A and 2A).
Mice transplanted with GDF-15 deficient bone marrow
showed enhanced expression of intercellular adhesion
molecule-1 (ICAM-1)
ICAM-1 staining was enhanced in atherosclerotic lesions
of chimeric mice (0.41 versus 0.25 in wild-type controls,
p<0.01; Figures 1B and 2B).
Features of lesion composition
Video-microscopic evaluation of features of lesion-
destabilization showed significantly more thinning of the
fibrous cap in LDLr−/− mice transplanted with bone
marrow from GDF-15−/− mice than in controls (48.5 μm
C D
BA
Figure 2 Macrophage staining of the aortic root of a LDLr−/−mouse, transplanted with bone marrow from a GDF-15−/−donor
(A) demonstrated an enhanced macrophage accumulation (arrows) within the atherosclerotic lesion compared to a control animal (B).
Staining for ICAM-1 furthermore showed an increased expression (arrows) in animals transplanted with GDF-15 deficient bone marrow (C) in
contrast to controls (D). Pictures demonstrate a colocalization of macrophages and ICAM-1.
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any difference in size of the necrotic core or calcification
within the lesions (data not shown).
Discussion
Recent studies have hypothesized a crucial role of the
cytokine GDF-15 in cardiovascular diseases. While clin-
ical investigations demonstrate GDF-15 as a parameter
for risk stratification in myocardial infarction and heart
failure, experimental studies show a cardio-protective ef-
fect in ischemia and reperfusion [7,10-13];furthermore,
GDF-15 is correlated with systemic inflammation [21].
These data suggest an involvement of GDF-15 in the ini-
tiation and progression of atherosclerosis. Recently, de
Jager et al. demonstrated an anti-atherosclerotic effect of
GDF-15 deficiency in a mouse model of atherosclerosis
[17]. The authors used LDLr−/− mice transplanted with
GDF-15-deficient bone marrow. In this study, GDF-15
deficiency resulted in a reduction of early atherosclerotic
lesion size after 4 weeks on a high cholesterol western-
type diet. After 12 weeks, no differences in lesion size
could be detected. Using mice following 24 weeks on a
western-type diet, we focused on more advanced and
complex lesions to model late-stage disease. It is known
that lesions in mice become quite complex with in-
creased duration of feeding [22]. We could not detect
any differences in lesion size, but in contrast to thefindings of de Jager et al., our data demonstrated a pro-
inflammatory plaque phenotype in mice transplanted
with bone marrow from GDF-15−/− donors with en-
hanced macrophage accumulation [17]. In the present
study macrophages were identified by using a Mac-2
antibody, which is an appropriate staining used in many
LDLr−/− mouse studies. We cannot exclude that staining
for other macrophage markers will identify different sub-
populations of macrophages with different results. The
increase seen in our study was accompanied by en-
hanced expression of ICAM-1 within lesions.
Monocyte/macrophage recruitment is dependent on
adhesion molecules [23]. ICAM-1 is mostly expressed by
endothelial cells but also in macrophages within athero-
sclerotic lesions and it is supposed to be involved in
foam cell transformation of monocytes and therefore
contributes to changes in lesion vulnerability [24,25].
Our data also confirm a correlation between enhanced
macrophage content and signs of the vulnerable plaque
determined by the thickness of fibrous caps. This is in
line with autopsy findings of ruptured plaques in human
[26]. Macrophages excrete an excess of matrix-degrading
enzymes and macrophage-rich lesions, and therefore
most likely undergo thinning of the fibrous caps and
subsequent enhanced vulnerability followed by plaque
rupture [27,28]. However, our findings of an association
between GDF-15 deficiency and reduced plaque stability
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decreased necrotic core formation in GDF-15−/− chimera
is reported [17]. It is known that at one point in athero-
sclerotic lesion development, changes in plaque compos-
ition but not progression of size,are dominating. The
increase in macrophages and the subsequent increase in
inner-plaque inflammation finally results in a reduction
of plaque stability. Other than the effect on fibrous caps,
we could not detect any differences in other features of
lesion destabilization, which might also be due to the
duration of the study and the animal model since it is
known that differences in necrotic core and hemorrhage
are more common in brachiocephalic arteries in apoE−/−
mice [29].
There are several limitations to our study. Investigat-
ing atherosclerotic lesions in LDLr−/− mice is mostly
done in the aortic root, which is not a typical lesion lo-
cation. It is known as a model of early stages in athero-
sclerosis and does not show much progress in late-stage
disease [30,31]. We did not focus on the onset of athero-
sclerotic changes within the vascular wall such as lipid ac-
cumulation in younger mice. Evaluation of fibrous caps
was performed morphometrically as in many LDLr−/−
mouse studies. Given the amount of tissue obtained, we
were not able to stain for other parameters such as the dif-
ferences in collagen content. Further, we do not know if
bone-marrow transplantation has an effect on other cyto-
kines, the immunosystem, or metabolism, which is an im-
portant factor in atherosclerosis. Recently, it has been
shown that GDF-15 is a key regulator in anorexia,
and weight and fat loss [32]. However, lipid levels and
body weight in our study were equally distributed.
We could not detect any further change in lethality
after transplantation.
Conclusions
In conclusion, this is the first study evaluating the effects
of GDF-15 in advanced stages of atherosclerosis. We
were able to demonstrate a GDF-15-dependent inhib-
ition of macrophage adhesion and accumulation in an
atherosclerotic LDLr−/− mouse model. This effect may
contribute to changes in lesion vulnerability such as
thinning of fibrous caps and potential plaque rupture.
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